Extract
In a recent paper published in the European Respiratory Journal, we studied the characteristics, trajectory and mortality of subjects with Preserved Ratio Impaired Spirometry (PRISm) in the Rotterdam Study, a prospective population-based cohort study in the Netherlands, a high-income country (HIC) [1]. In an elegant letter to the editor, P. Jackson and T. Siddharthan correctly argue that clinical research on PRISm has been limited so far in its potential to grasp a representative sample of the world population, with marked underrepresentation of studies in low- and middle-income countries (LMICs). Despite potential differences in risk factors, they suggest that systemic inflammation plays a key role in the pathogenesis of PRISm in both HIC and LMICs.
Abstract
Subjects with PRISm represent a heterogeneous population encompassing distinct phenotypes with distinct risk factors. A spectrum of mechanisms and risk factors contribute to varying degrees to the pathogenesis of PRISm in different populations. http://bit.ly/2TkHJjK
Footnotes
Conflict of interest: S.R.A. Wijnant reports grants from GlaxoSmithKline, outside the submitted work.
Conflict of interest: L. Lahousse reports grants from AstraZeneca and Chiesi (both awards), and expert consultation for Boehringer Ingelheim GmbH and Novartis, outside the submitted work.
Conflict of interest: G.G. Brusselle reports personal fees for advisory board work and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work.
- Received February 18, 2020.
- Accepted February 19, 2020.
- Copyright ©ERS 2020